Article
Computer Science, Information Systems
Lu Zeng, Hengxin Li, Tingsong Xiao, Fumin Shen, Zhi Zhong
Summary: This paper proposes a two-phase framework to address the issues of training set bias and interpretability in early Alzheimer's disease (AD) diagnosis. By automatically distinguishing samples and assigning weights, the proposed method achieves better classification performance and interpretability.
INFORMATION PROCESSING & MANAGEMENT
(2022)
Article
Health Care Sciences & Services
Giulia Giacomucci, Salvatore Mazzeo, Silvia Bagnoli, Matteo Casini, Sonia Padiglioni, Cristina Polito, Valentina Berti, Juri Balestrini, Camilla Ferrari, Gemma Lombardi, Assunta Ingannato, Sandro Sorbi, Benedetta Nacmias, Valentina Bessi
Summary: This study compared different CSF amyloid biomarkers and amyloid-PET in patients with AD and FTD, finding that CSF A beta(42/40) ratio significantly increased the diagnostic accuracy, and suggested a flowchart for biomarker use based on clinical suspicion.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Endocrinology & Metabolism
John Zhou, Marc Benoit, Md Golam Sharoar
Summary: Alzheimer's disease (AD) currently has no known cures or disease modifying treatments (DMTs), but early diagnosis and intervention during the pre-symptomatic phase is considered an effective strategy. Biomarkers have emerged as a critical tool for monitoring the effect of new AD therapies and identifying patients likely to respond to treatment. The establishment of the A/T/N framework in 2018 has codified the contexts of use of AD biomarkers for research and diagnostic purposes, leading to a renewed drive for novel biomarkers and innovative detection methods in the field.
METABOLIC BRAIN DISEASE
(2022)
Article
Biotechnology & Applied Microbiology
Johannes Geibel, Christian Reimer, Torsten Pook, Steffen Weigend, Annett Weigend, Henner Simianer
Summary: This study proposes an alternative approach to mitigate SNP ascertainment bias by using information from a small set of sequenced individuals, without prior knowledge of the array design. Results showed that a reference panel with at least one individual per population can effectively correct ascertainment bias for estimates of genetic parameters.
Article
Clinical Neurology
Thomas K. Karikari, Andreja Emersic, Agathe Vrillon, Juan Lantero-Rodriguez, Nicholas J. Ashton, Milica Gregoric Kramberger, Julien Dumurgier, Claire Hourregue, Sasa Cucnik, Gunnar Brinkmalm, Uros Rot, Henrik Zetterberg, Claire Paquet, Kaj Blennow
Summary: Phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) is a biomarker for Alzheimer's disease (AD), and novel immunoassays targeting different fragments of p-tau provide better diagnostic accuracy for MCI-AD and AD dementia, especially in relation to A beta pathophysiology.
ALZHEIMERS & DEMENTIA
(2021)
Article
Clinical Neurology
Timothy Schmutte, Mark Olfson, Donovan T. Maust, Ming Xie, Steven C. Marcus
Summary: The study found that in the first year after a diagnosis of ADRD, the suicide rate is higher among ADRD patients compared to the general geriatric population, especially in adults aged 65 to 74, with a significantly high risk. Factors such as rural residence, recent mental health issues, substance abuse, and chronic pain conditions were associated with an increased risk of suicide.
ALZHEIMERS & DEMENTIA
(2022)
Article
Chemistry, Analytical
Goksu Ozcelikay, Maria Gamella, Mehmet Altay Unal, Kivilcim Gucuyener, Ana Montero-Calle, Rodrigo Barderas, Jose M. Pingarron, Susana Campuzano, Sibel A. Ozkan
Summary: This study presents a magnetic microbeads-based electrochemical immunoplatform for the detection of GFAP, which has potential clinical applications in the diagnosis and prognosis of neurodegenerative diseases. The platform demonstrates low detection limit, good selectivity, and the ability to differentiate between healthy individuals and patients with VD and AD.
Review
Chemistry, Multidisciplinary
Shima Tajahmadi, Hossein Molavi, Farhad Ahmadijokani, Amir Shamloo, Akbar Shojaei, Mohammad Sharifzadeh, Mashallah Rezakazemi, Ali Fatehizadeh, Tejraj M. Aminabhavi, Mohammad Arjmand
Summary: Beta-amyloid (Al3) peptide is a key biomarker of Alzheimer's disease (AD), and monitoring its levels is crucial for early diagnosis, prevention, and treatment. Recent attention has focused on the potential of metal-organic frameworks (MOFs) for AD diagnosis and treatment. This review discusses the latest advances in using MOFs for early detection of AD biomarkers, detection of metal ions in the brain, and imaging of Al3 plaques.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Biochemistry & Molecular Biology
Carmen Pena-Bautista, Lourdes Alvarez-Sanchez, Ines Ferrer, Marina Lopez-Nogueroles, Antonio Jose Canada-Martinez, Camille Oger, Jean-Marie Galano, Thierry Durand, Miguel Baquero, Consuelo Chafer-Pericas
Summary: Alzheimer's Disease (AD) is a common neurodegenerative disease in aging populations, with complex diagnosis usually performed in advanced stages. Plasma isoprostanoids may serve as useful biomarkers for preclinical diagnosis of AD, as shown in the study, but further validation is warranted.
Article
Radiology, Nuclear Medicine & Medical Imaging
Ho Young Park, Woo Hyun Shim, Chong Hyun Suh, Hwon Heo, Hyun Woo Oh, Jinyoung Kim, Jinkyeong Sung, Jae-Sung Lim, Jae-Hong Lee, Ho Sung Kim, Sang Joon Kim
Summary: This study developed an automatic classification algorithm for diagnosing Alzheimer's disease (AD) or mild cognitive impairment (MCI) and compared its performance with the widely used classifier XGBoost. The results showed that TabNet achieved high performance in AD classification and provided detailed interpretation of the selected regions.
EUROPEAN RADIOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Chun-Hung Chang, Chieh-Hsin Lin, Hsien-Yuan Lane
Summary: This study investigated the application of machine learning and novel biomarkers in the diagnosis of Alzheimer's disease (AD). In addition to traditional Aβ and tau-related biomarkers, biomarkers related to neuronal injury, synaptic dysfunction, and neuroinflammation were explored. Machine learning combined with novel biomarkers and multiple variables may improve the sensitivity and specificity in diagnosing AD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Clinical Neurology
Jonviea D. Chamberlain, Anais Rouanet, Bruno Dubois, Florence Pasquier, Olivier Hanon, Audrey Gabelle, Mathieu Ceccaldi, Pierre Krolak-Salmon, Yannick Bejot, Olivier Godefroy, David Wallon, Armelle Gentric, Genevieve Chene, Carole Dufouil
Summary: The study found that incident cancer was associated with a reduced risk of dementia, suggesting a protective relationship between cancer and dementia. Further investigations are encouraged to understand potential underlying mechanisms.
ALZHEIMERS & DEMENTIA
(2021)
Article
Biophysics
Sojin Song, Jong Uk Lee, Myeong Jin Jeon, Soohyun Kim, Chan-Nyoung Lee, Sang Jun Sim
Summary: Alzheimer's disease is a neurodegenerative condition that is challenging to diagnose early due to the lack of robust biomarkers and limited access to neuroimaging and cerebrospinal fluid tests. Exosomes in body fluids are being explored as diagnostic biomarkers that reflect neuropathological features. A programmable curved plasmonic nanoarchitecture-based biosensor has been developed to accurately diagnose Alzheimer's disease.
BIOSENSORS & BIOELECTRONICS
(2023)
Article
Clinical Neurology
Malte Klingenberg, Didem Stark, Fabian Eitel, Celine Budding, Mohamad Habes, Kerstin Ritter, Alzheimers Dis Neuroimaging Initiat
Summary: This study trained a convolutional neural network using a balanced dataset to detect Alzheimer's disease. The results showed that the machine learning classifier had different performance for men and women, indicating the presence of sex bias. The findings emphasize the importance of examining and reporting classifier performance across population subgroups to ensure algorithmic fairness.
ALZHEIMERS RESEARCH & THERAPY
(2023)
Article
Medical Laboratory Technology
Yutong Zou, Songlin Yu, Xiaoli Ma, Chaochao Ma, Chenhui Mao, Danni Mu, Lei Li, Jing Gao, Ling Qiu
Summary: Cerebrospinal fluid (CSF) beta-amyloid (Aβ) is crucial for the early diagnosis of Alzheimer's disease (AD). However, there is significant variation in cohort distributions and cut-off values across different analytical assays, kits, and laboratories. This review summarizes the cut-off values and diagnostic performance for CSF Aβ 1-42 and Aβ 142/Aβ 1-40, and examines the important factors that affect them.
CLINICAL BIOCHEMISTRY
(2023)